Recent Expansion Science 37 has launched a new stand-alone Patient Recruitment Solution, indicating a focus on expanding service offerings and potentially creating opportunities for partnership or collaboration.

Acquisition eMed LLC's acquisition of Science 37 for $38M presents a sales opportunity to leverage the combined strengths of both companies to enhance service delivery and seek new business prospects in the decentralized trial market.

Partnerships Partnerships with companies like Citeline Connect and SCRS showcase Science 37's commitment to collaboration. Utilizing these partnerships can open avenues for joint ventures and increased market reach.

Industry Recognition Being recognized as a Leader in Decentralized Clinical Trials by Everest Group for three consecutive years positions Science 37 as a reputable player in the industry. Leveraging this recognition can help attract new clients seeking reliable research solutions.

Financials & Funding With a revenue range of $100M - 1B and $200M in funding, Science 37 exhibits financial stability. This financial health can instill confidence in potential clients looking for long-term partnerships.